SCHEMBL6359861

SCHEMBL6359861

Cc1ccc(Nc2cc(N3CCN(c4ncccn4)CC3)nc(N3C[C@@H](C)O[C@@H](C)C3)n2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.48
LMNA P02545 2/20 0.48
GALR1 P47211 5/20 0.46
GALR2 O43603 5/20 0.46
PIK3CA P42336 1/20 0.41
ROCK2 O75116 1/20 0.40
ROCK1 Q13464 1/20 0.40
APAF1 O14727 1/20 0.40
GAA P10253 1/20 0.40
PPP1CA P62136 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
AURKA O14965 1/20 0.40
BLM P54132 1/20 0.39
TRPV1 Q8NER1 2/20 0.39
GBA1 P04062 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3240588 0.85 GALR2 (0.59) MAPTLMNAGALR1GALR2APAF1
SCHEMBL3241392 0.78 GALR2 (0.59) MAPTLMNAGALR1GALR2APAF1
SCHEMBL3245932 0.76 GALR2 (0.61) MAPTLMNAGALR1GALR2APAF1
SCHEMBL3240980 0.76 GALR2 (0.62) MAPTLMNAGALR1GALR2APAF1
SCHEMBL6359862 0.75 GALR1 (0.40) MAPTLMNAGALR1GALR2ROCK1
SCHEMBL6359858 0.75 GALR1 (0.40) MAPTLMNAGALR1GALR2ROCK1
SCHEMBL6662851 0.74 GALR2 (0.60) MAPTLMNAGALR1GALR2APAF1
SCHEMBL3240927 0.73 GALR2 (0.77) MAPTLMNAGALR1GALR2APAF1
SCHEMBL5455407 0.72 GALR2 (0.68) MAPTLMNAGALR1GALR2TRPV1
SCHEMBL3241078 0.72 GALR2 (0.57) MAPTLMNAGALR1GALR2APAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936607-B2 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety H. LUNOBECK A/S (DK) 2005-08-30 US disclosed
US-20040082587-A1 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety H. LUNDBECK A/S (DK) 2004-04-29 US disclosed
US-20040082587-A1 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety H. LUNDBECK A/S (DK) 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082587-A1 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety GALR3, GALR2, GALR1 MAPT 2638/4885LMNA 3975/4885GALR1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.